Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of AVP-923 in Applesauce or NG Tube vs Capsule
NCT03381664Phase 1Completed
- Sponsor
- Avanir Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Jan 2018
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dextromethorphan + quinidine in pseudobulbar affect (PBA) (3 arms), sponsored by Avanir Pharmaceuticals. Primary endpoints: Area under the concentration-time curve from time 0 to last measurable concentration at 48 hours, Area under the concentration-time curve from time 0 to infinity at 48 hours and 4 more. Started Nov 2017; status: completed.
02
Drugs
dextromethorphan + quinidine
03
Conditions
pseudobulbar affect (PBA)
Beyond the preview
Go deeper on NCT03381664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381664.